A GITRL‐mTORC1‐GM‐CSF positive loop promotes pathogenic Th17 response in exacerbating Primary Sjögren's Syndrome

Yuzhou Gan,Haotian Zhou,Yixue Guo,Bo Huang,Hongjiang Liu,Ziye Wang,Zijun Li,Xiaozhen Zhao,Huaqun Zhu,Qimao Han,Hua Ye,Jing He,Qingwen Wang,Zhanguo Li,Xiaolin Sun
DOI: https://doi.org/10.1002/art.42859
2024-04-10
Arthritis & Rheumatology
Abstract:s Objectives Glucocorticoid‐induced Tumor‐Necrosis‐Factor‐Receptor Family‐related Protein (GITR), with its ligand (GITRL), plays an important role in CD4+T‐cell‐mediated autoimmunity. This study aimed to investigate the underlying mechanisms of GITRL in primary Sjögren's Syndrome (pSS). Methods pSS patients and healthy controls were recruited. Serum GITRL and Th17‐related cytokines were determinated. RNA‐Sequencing was performed to decipher key signal pathways. Non Obese Diabetes (NOD) mice was adopted as experimental Sjögren models and recombinant adeno‐associated virus (rAAV) transduction was conducted to verify the therapeutic potentials of targeting GITRL in vivo. Results Serum GITRL was significantly higher in pSS patients and showed a positive correlation with leukopenia, thrombocytopenia, autoantibodies, lung involvement and disease activity. Serum GITRL was correlated with Th17‐related cytokines. GITRL promoted expansion of Th17 and Th17.1 cells. Expansion of granulocyte‐macrophage‐colony‐stimulating‐factor (GM‐CSF+)CD4+T cells induced by GITRL could be inhibited by blockade of GITRL. Moreover, GM‐CSF could stimulate GITRL expression on monocytes. RNA‐Sequencing revealed mammalian target of rapamycin complexes 1 (mTORC1) might be the key modulator. The increased phosphorylation of S6 and STAT3 and expansion of Th17 and Th17.1 cells induced by GITRL were effectively inhibited by rapamycin, suggesting a GITRL/mTORC1/GM‐CSF positive loop in pathogenic Th17 response in pSS. Administration of rAAV vector expressing shRNA targeting GITRL alleviated disease progression in NOD mice. Conclusions Our results identified the pathogenic role of GITRL in exacerbating disease activity and promoting pathogenic Th17 response in pSS through a GITRL/mTORC1/GM‐CSF positive loop. These findings suggest GITRL might be a promising therapeutic target in the treatment of pSS.
rheumatology
What problem does this paper attempt to address?